Introduction
Androgens and the androgen receptor (AR) are critical in the development and differentiation of the prostate gland, as well as in prostate tumorigenesis (Culig et al., 2000; Grossmann et al., 2001; Gelmann, 2002; Chen et al., 2004; Taplin and Balk, 2004) . Since Huggins and Hodges demonstrated that prostate cancer (CaP) was an androgen-dependent neoplasm, androgen ablation therapy has been the cornerstone for treatment of metastatic CaP (Huggins and Hodges, 1941; Grossmann et al., 2001; Gelmann, 2002) . However, after a period of initial response to androgen ablation the vast majority of patients eventually relapse, at which point the disease is defined as 'hormone refractory.' Molecular mechanisms involved in androgen ablation-mediated apoptosis and androgen ablation refractory features of CaP cells are under active investigation (Culig et al., 2000; Grossmann et al., 2001; Gelmann, 2002; Shi et al., 2002; Chen et al., 2004) , and may involve dysfunctions of AR, p53, PTEN, AKT, BCL2 and HER2 (Culig et al., 2000; Feldman and Feldman, 2001; Grossmann et al., 2001; Gelmann, 2002) . AR signaling has been widely studied for the potential role in CaP progression. CaP associated alterations of AR functions by mechanisms involving AR gene amplification, AR mutations, elevated AR mRNA or AR protein levels, altered AR interaction with co-activators and co-repressors and ligand independent AR activation by growth factors or cytokines may contribute to the CaP progression Grossmann et al., 2001; Gelmann, 2002; Shi et al., 2002) . A recent study defining molecular mechanisms for the progression of the androgen responsive CaP cells to androgen independent status in xenograft models has highlighted increased wt AR expression as the only consistent gene expression change in androgen independent cells (Chen et al., 2004) .
Although, numerous mutations of AR have been shown to be associated during prostate cancer progression in humans (Grossmann et al., 2001; Gelmann, 2002; Shi et al., 2002) or in transgenic mice (Han et al., 2005) , the functional role of these changes in CaP progression are not clear. A recent report has established the functional role of one AR mutation (E231G) in CaP development in transgenic mouse model (Han et al., 2005) . Our study focuses on cancer biology related functions of the widely studied CaP associated AR mutation (mt AR, T877A) that was originally described in LNCaP cells. LNCaP-AR mutation, as well as other AR mutations have been subsequently reported in a subset of metastatic prostate cancers and cell lines derived from metastatic CaP (Gaddipati et al., 1994 , Taplin et al., 1999 , Culig et al., 2000 Grossmann et al., 2001; Gelmann, 2002; Taplin and Balk, 2004) . Earlier studies of the LNCaP-AR mutation and characterization of numerous CaP associated AR mutations have shown varying characteristics with one recurring theme of altered ligand binding specificity leading to the activation of transcription factor activity of AR in response to other ligands in addition to the androgens (Grossmann et al., 2001; Gelmann, 2002; Taplin and Balk, 2004) . In this regard, AR T877A may represent a prototypical mt AR with respect to structure-function evaluations of CaP associated AR mutations. Several studies have shown that the LNCaP cell variants selected under androgen-deprived media may harbor some alterations of AR. These cells exhibit increased cell proliferative features (Schuurmans et al., 1990; Veldscholte et al., 1990; Culig et al., 1999) . Furthermore, downregulation of AR in LNCaP cells by anti-AR antibodies (Zegarra-Moro et al., 2002) and AR-antisense or AR-siRNA oligonucleotides (Haag et al., 2005; Liao et al., 2005) have strongly suggested a role for AR functions in the survival of AR positive CaP cells.
Despite the numerous studies of AR signaling and AR associated functions in LNCaP cells, the direct role of the widely studied LNCaP-AR mutation or other CaP-AR mutations in CaP cell growth and survival promotion has not been established. To address this question, we expressed wt or mt (T877A) alleles of AR genes in CaP cell in either endogenous wt AR or endogenous mt AR (T877A) background. For this purpose, we used LNCaP cells that express endogenous mt AR (T877A) or LAPC4 cells that express wt endogenous AR. The effects of wt AR and mt AR (T877A) expression were analysed on cell growth, apoptosis and AR-transcription activation functions. Our study provides novel insights into the biological role of the AR (T877A) mutation that may lead to the understanding of functionally similar AR alterations in cell growth promotion and cell survival. These observations also have important implications for developing rational prognostic biomarker and therapeutic strategies for CaP showing AR dysfunctions.
Results

Mutant AR (T877A) promotes cell growth
To compare the biologic functions of the wt AR and the mt AR (T877A), LNCaP and LAPC4 cells were infected with Ad-wtAR, Ad-mtAR (T877A) or Ad-control. In LNCaP cells, there was approximately a three-fold increase of exogenous wt AR or mt AR (T877A) expression was observed in comparison to the endogenous AR levels (Figure 1a) . In LAPC4 cells there was approximately a six-fold increase of exogenous wt AR or mt AR (T877A) expression was detected over the endogenous wt AR (Figure 1b) .
To analyse the effects of mt AR (T877A) or wt AR expression on cell growth, Ad-wtAR and Ad-mtAR (T877A) infected LNCaP or LAPC4 cells were cultured in cFBS containing medium in the absence or presence of R1881 (1pM-1nM). Ad-control infected LNCaP and LAPC4 cells were treated in parallel as a control. In the absence of R1881, Ad-mtAR (T877A) infected cells showed increased cell proliferation compared to AdwtAR and Ad-control infected cells (Po0.01, Figure 2a endogenous mt AR (Culig et al., 1999) . These results indicated that increased mt AR (T877A) expression enhanced the growth of both LNCaP and LAPC4 cells in the absence of R1881 and also showed enhanced cell proliferation response to lower concentrations of R1881. Furthermore, bicalutamide did not inhibit the growth of mt AR (T877A) overexpressing cells in the absence of R1881 (Supplementary Figure 2) .
Transcriptional activation function of mutant AR (T877A) is independent of exogenous androgen Wild type AR and mt AR (T877A) conferred strikingly different cell growth characteristics in both LNCaP and LAPC4 cells. Transcriptional regulatory functions of wt AR and mt AR (T877A) were assessed by monitoring the expression of a known AR transcriptional target, PSA/KLK3. Secreted PSA protein was measured in cell culture medium of cells infected with Ad-wtAR and AdmtAR (T877A) (Figure 3a and b). As expected, AdwtAR infected LNCaP or LAPC4 cells expressed low basal levels of PSA protein in the absence of R1881 that could be induced by the addition of R1881 to the medium. In contrast, increased levels of PSA protein were detected when mt AR (T877A) was expressed in LNCaP or LAPC4 cells with or without R1881 treatment. These results suggested that the expression of the mt AR (T877A) led to increased PSA expression in LNCaP or LAPC4 cells even in the absence of R1881 stimuli. These data also indicated that LNCaP and LAPC4 cells expressing endogenous wt AR or mt AR continued to be responsive to R1881 when higher levels of exogenous wt AR were introduced. These data sharply point to differences in the activation of the wt AR and mt AR functions under comparable experimental conditions and controlled expression levels in two different prostate cancer cell line backgrounds. Further, the addition of bicalutamide to the cell culture medium did not inhibit PSA levels in Ad-mtAR (T877A) infected LNCaP or LAPC4 cells in the absence of R1881. This observation is consistent with previous reports (Culig et al., 1999; Chen et al., 2004) .
To assess changes in PSA transcription levels in exogenous mt AR expressing LNCaP cells, Northern blot analysis was performed ( Figure 3c ). In Ad-wtAR and Ad-control infected LNCaP cells, lower basal expression of PSA/KLK3 mRNA was observed in the absence of R1881, and the transcription was up regulated in the presence of R1881. Increased levels of PSA mRNA were detected in Ad-mtAR (T877A) infected LNCaP cells in the absence of R1881, which consistently remained at high levels in the presence or absence of R1881 treatment. These results were consistent with the results of PSA protein measurements in cell culture supernatants. PSA promoter luciferase reporter assay using LNCaP cells infected with AdwtAR, Ad-mtAR (T877A) or Ad-control (Figure 3d ) essentially showed similar results. PSA promoter-driven luciferase activity in Ad-mtAR (T877A) infected LNCaP cells was significantly higher than in Ad-wtAR or Ad-control infected LNCaP cells in the absence of R1881 (Po0.001).
Taken together, based on the results of three independent approaches, we concluded that the mt AR (T877A) is a robust transcriptional activator when compared to wt AR.
Mutant AR (T877A) confers resistance to cell growth inhibition and apoptosis mediated by the p53 tumor suppressor gene Previous studies showed that increased levels of both endogenous and exogenous wt p53 led to growth inhibition and apoptosis of CaP cells in vitro and in vivo (Heidenberg et al., 1995; Yang et al., 1995; Ioffe et al., 2004) . To investigate the effects of increased AR (T877A) expression on p53 mediated cell growth inhibition and apoptosis, we performed colony formation assays with LNCaP cells that were coinfected with Ad-wtp53 and Ad-mtAR (T877A) or Ad-wtp53 and AdwtAR or Ad-wtp53 and Ad-control. As an alternative approach, we evaluated the effects of the mt AR (T877A) on endogenous wt p53 functions, Ad-mtAR (T877A), Ad-wtAR or Ad-control infected LNCaP cells treated with Dx (0.2 mg/ml) (Figure 4a and b) . Infection of Ad-wtp53 or induction of wt p53 with Dx resulted in higher levels of p53. Only low levels of p53 were detected in control LNCaP cells. As a p53-regulated gene, the upregulation of p21 waf1 expression was confirmed in LNCaP cells that expressed higher levels of exogenous wt p53 or Dx induced wt p53 suggesting the activation of wt p53 in these cells. Consistent with previous studies, cell growth and colony-forming ability were severely inhibited by the infection of Ad-wt p53 or induction of p53 by Dx in Ad-control infected LNCaP cells (Heidenberg et al, 1995; Yang et al., 1995; Tsui et al., 2004) (Figure 5 ). In contrast, Ad-mtAR (T877A) infected LNCaP cells exhibited striking resistance to cell growth inhibition mediated by exogenous wt p53 or Dx induced endogenous wt p53 in the absence or presence of R1881, suggesting that expression of mt AR (T877A) provides cell growth/survival advantage and abrogates cell growth inhibition and/or apoptosis induced by p53 in CaP cells. Ad-wtAR overexpressing LNCaP cells showed measurable resistance to cell growth inhibition mediated by exogenous or endogenous p53 in the presence of R1881. Owing to the presence of p53 mutation in LAPC4 cells (van Bokhoven et al., 2003) , this experiment was not performed with LAPC4 cells.
The cell morphological features of Ad-mtAR (T877A), Ad-wtAR or Ad-control infected LNCaP cells were examined at day 5 after Dx treatment (Figure 6a) . In contrast to the detachment of Ad-wtAR or Adcontrol infected LNCaP cells, Ad-mtAR (T877A) infected LNCaP cells continued to grow with or without R1881. Ad-mtAR (T877A), Ad-wtAR or Ad-control infected LNCaP cells were harvested for apoptotic DNA ladder analysis at day 5 after induction of Dx (Figure 6b ). Significant DNA fragmentation was observed in Ad-control with slight inhibition noted for Ad-wtAR infected LNCaP cells and a significant inhibition was observed with Ad-mtAR (T877A) infected LNCaP cells.
Discussion
Accumulating data suggests that altered AR functions due to elevated AR expression, AR amplification, AR mutation or cross-talk with other cell growth/survival signaling pathways associate with a significant subset of advanced CaPs. These types of tumors are often treatment refractory (Grossmann et al., 2001; Gelmann, 2002) . Numerous studies support the notion that altered AR signaling contributes to the progression of CaP to advanced stages, including treatment resistant disease (Culig et al., 2000; Grossmann et al., 2001; Gelmann, 2002; Chen et al., 2004; Taplin and Balk, 2004) . Results from several laboratories imply that AR mutations leading to amino-acid substitutions may affect the binding of AR to steroids, androgen-responsive elements, heat shock proteins; and to coactivators or corepressors. Furthermore, these results lead to the alteration of AR transcription factor functions Culig et al., 2000; Chen et al., 2004; Taplin and Balk, 2004) . Therefore, it is suggested that proliferation of tumor cells expressing elevated wt AR or mt AR may be selected for cell growth and survival by abrogating the normal cell growth regulatory circuits.
This study provides a mechanistic model on the basis of direct experimental evidence showing that a widely studied AR mutation (T877A) in CaP cells promotes cell growth/cell survival that can be reconciled with its potential biological functions in prostate cancer progression. Our results showed that mt AR (T877A) exhibited robust AR transcriptional activity and caused enhanced cell growth in LNCaP or LAPC4 cell background in the absence of R1881. These characteristics of the mt AR could not be inhibited by nonsteroidal antiandrogen, bicalutamide and these data are consistent with previous observations showing the ineffectiveness of bicalutamide in inhibiting AR even when modestly elevated levels of either wt or mt AR are present in cells (Culig et al., 1999; Chen et al., 2004) . It was further confirmed that LNCaP or LAPC4 cells harboring high levels of mt AR (T877A) were more sensitive to very low R1881 concentrations. It is likely that the mt AR (T877A) through its broader ligand binding characteristics may be activated in the absence of androgens Taplin and Balk, 2004) . Importantly, this study supports the causal link of an AR mutation to CaP progression by showing that mt AR (T877A) confers increased cell growth and/or abrogated apoptotic signals in CaP cells. A recent report studying the tumorigenic potential of AR mutations has shown transforming potential of an AR mutation (E231G) in transgenic mice model of prostate cancer. However, this study did not reveal the phenotypic effect of mouse mt AR (T857A), that is equivalent to human mt AR (T877A) (Han et al., 2005) . The data reported here is showing the apparent phenotypic differences of the Ad-mtAR (T877A) in LNCaP and LAPC4 cell culture models. It is plausible that LNCaP, as well as LAPC4 cellular and genomic context, is more compatible for registering the cell biological effects of T877A AR mutation.
AR mutations are mostly associated with disease progression and both LNCaP and LAPC4 represent metastatic CaP-derived cell lines. Since Bcl-2 and p-Akt has been implicated in providing CaP cell survival advantage in the absence of androgen (Raffo et al., 1995; Wen et al., 2000) , we assessed the expression of Bcl-2 and p-Akt by Western blot analysis in Ad-mtAR (T877A), Ad-wtAR or Ad-control infected LNCaP cells. However, ectopic expression of wt AR or mt AR (T877A) did not affect the status of cellular p-AKT or BCL2 (data not shown).
To our knowledge, this is the first report showing that increased expression of mt AR or wt AR provides resistance to cell growth inhibition/apoptosis mediated by p53. Our findings presented here, offer the hypothesis that AR mutation(s) may promote the growth or survival of CaP cells by abrogating negative cell growth regulatory functions of the p53 during progression of CaP.
Cumulative evidences suggest that p53 gene alterations are associated with CaP progression and p53 alteration in CaP may be a poor prognostic factor (Bauer et al., 1995; Heidenberg et al., 1995; Small, 1998) . The p53 tumor suppressor is a transcription factor that regulates the expression of genes involved in the maintenance of genomic integrity in response to diverse genomic and cellular stress stimuli (Arrowsmith, 1999; Landis et al., 1999; Yap et al., 1999) . Therefore, defects of p53 may contribute to the survival of tumor cells harboring AR dysfunctions. It is interesting to note that the majority of metastatic CaP-derived cell lines (seven out of eight) described in the literature (Sobel and Sadar, 2005) harbor mutations of AR and/or p53 suggesting for critical roles of these pathways in CaP progression. These observations have significant implications for developing biomarkers that can monitor the disease progression and therapeutic response and for developing new therapeutic strategies of CaP. The presence of AR mutations may in fact be a reliable indicator of the selection of therapeutic strategy used. Based on this report, as well as other studies focusing on AR alteration associated dysfunctions in CaP cells, currently used therapies focusing on androgen ablation may not be appropriate for tumors showing AR dysfunctions. Efficient targeting of the mt ARs for destruction and/or super-activation of wt p53 may provide more effective therapeutic strategy for treating metastatic CaP harboring the type of AR dysfunction reported here. While this manuscript was in revision, a recent report suggested that there may be a mutual regulation of expression between p53 and AR protein in LNCaP cells (Rokhlin et al., 2005) . This report together with our study underscores AR-p53 cross talks by mechanisms not yet well understood. Future studies of functional evaluations of the AR and p53 cross-talks and dysfunctions in CaP cells hold promise in defining the causal role of these two pathways in CaP progression and in developing new treatment strategies for the treatment-resistant CaP.
Materials and methods
Cell lines and reagents
Prostate cancer cells: LNCaP and human embryonic kidney cells 293 were obtained from ATCC (Rockville, MD, USA). LAPC4 cells were kindly provided by Dr Charles L Sawyers (UCLA, CA, USA). All cells were maintained in culture medium recommended by the supplier at 371C in a 5% CO 2 incubator. R1881, a synthetic analogue of androgen, was purchased from New England Nuclear (Boston, MA, USA). Bicalutamide, a nonsteroidal antiandrogen, was provided by AstraZeneca (Wilmington, DE, USA). Anti-AR antibody (sc-618) was purchased from Santa Cruz Biotechnology Laboratories (Santa Cruz, CA, USA). Anti-p53 and p21 waf1 antibodies were purchased from Cell Signaling (Beverly, MA, USA). Doxorubicin was purchased from Sigma (St Louis, MO, USA).
Construction of adenoviral expression vectors pCMV-AR, which contains complete coding region of human wt AR with extra 5 0 UTR (219 bp) and 3 0 UTR (291 bp) were described previously (Nakao et al., 1992) . pSG5-mt AR (T877A) which contains complete coding region of LNCaP-AR (mt AR , T877A) with extra 5 0 UTR (532bp) and 3 0 UTR (130 bp), were kindly provided by Dr Shutsung Liao (University of Chicago, IL, USA). First, pCMV-AR was digested with HindIII and XbaI and the C-terminal HindIII-XbaI fragment containing the ligand-binding domain with 3 0 UTR (291 bp) was deleted. The c-terminal HindIII-XbaI fragment containing the T877A mutation and 3 0 UTR (130 bp) was excised from pSG5-mtAR (T877A) and ligated to pCMV-AR to produce pCMV-mtAR (T877A) (Supplementary Figure 3) . The BglII-XbaI fragments containing wt AR or mt AR (T877A) cDNA were excised from pCMV-AR or pCMVmtAR (T877A) and subcloned into adenoviral transfer vector, pAdTrack-CMV (from Drs Kenneth Kinzler and Bert Vogelstein, Johns Hopkins University, Baltimore, MD, USA) at BglII and XbaI restriction endonuclease sites. The entire coding region of the wt AR and mt AR (T877A) was confirmed in the Ad-wtAR and Ad-mtAR (T877A) expression vector. The construction of adenoviral vector expressing wt p53 was described previously . The generation of recombinant adenovirus plasmid and production of recombinant adenovirus were performed as described before (He et al., 1998) . The recombinant virus expressing human wt AR, mt AR (T877A) or wt p53 were termed Ad-wtAR, AdmtAR (T877A) or Ad-wtp53, respectively. These adenovirus expression vectors also contain a Green Fluorescent Protein (GFP) expression cassette driven by a different promoter and GFP expression served as a convenient measure of the efficiency of the adenovirus infection in each experiment. Adenovirus titer was determined by GFP assay as well as a plaque forming assays (He et al., 1998) .
Adenovirus infections
To avoid adenovirus toxicity, the adenovirus were dialyzed and titered carefully and the desired dosages of adenoviruses (plaque-forming unit, pfu) were optimized for each cell type to provide high infection efficiency (more than 90%). The initial optimizations also helped define adenovirus titers that would not produce supra-physiological levels of AR or p53 but will yield comparable levels of ectopic expression wt AR, mt AR (T877A) or wt p53 in various cell culture models. The adenovirus infection performed as described previously . Briefly, LNCaP or LAPC4 cells were seeded into 10 cm tissue culture dishes at 3 Â 10 6 cells/dish in the appropriate medium with 10% charcoal/dextran-stripped FBS (cFBS, Gemini Bio-Products, Calabasas, CA, USA) for 5 days. The adenovirus infection of cells was initiated with a 2 h of incubation at 371C in 2 ml infection medium (the appropriate cell culture medium with 2% cFBS) and desired dosages of Ad-wtAR (5 pfu/cell), Ad-mtAR (T877A, 5 pfu/cell) or Adcontrol (5 pfu/cell) with/without Ad-wtp53 (1 pfu/cell). After 2 h, 7 ml of appropriate medium with 10% cFBS were added and the infection was continued for 24 h. The infected cells were processed for the following analysis.
Western blot analysis
At 48 h after infection, cell lysates were prepared in M-per protein extraction reagent (Pierce, Rockford, IL, USA). Western blot analyses were performed for the detection of AR, p53 and p21 waf1 (25 mg for AR detection, 50 mg for p53 and p21 waf1 detection). To observe the activation of endogenous p53 by Doxorubicin (Dx), cells were treated with Dx (0.2 mg/ ml) 24 h after infection with adenovirus expression vectors. At 48 h after Dx treatment, the cells were harvested for preparation of protein lysates.
Cell proliferation assays
LNCaP or LAPC4 cells were harvested 24 h after adenovirus infection and were subcultured in 96-well plates (5 Â 10 3 cells/ well) in the appropriate medium containing 10% cFBS without R1881 or with increasing concentration of R1881 (1 pM-1 nM). Bicalutamide (10 mM) treatment was included where indicated. Cell proliferation was determined at 1, 24, 48, 72 and 96 h after subculturing using CellTiter 96 Aqueous One Solution (Promega, Madison, WI, USA). The 1-h time point was included to confirm that an equal number of cells were present in the wells at the beginning of the experiment. This experiment was performed in quadruplicate and was repeated at least three times.
Detection of PSA expression by ELISA Immediately after adenovirus infection, LNCaP or LAPC4 cells were cultured in the appropriate medium containing 10% cFBS in the absence or presence of R1881 (100 pM). Parallel cell cultures were grown in the appropriate medium containing 10% cFBS with bicalutamide (10 mM). Cells were grown for 48 h (LNCaP) or 96 h (LAPC4). The cell culture conditioned medium was harvested and a PSA ELISA kit (Calbiotech, Spring Valley, CA, USA) was used to measure PSA expression in 100 ml of medium in triplicate as in the manufacturer's direction.
RNA preparation and Northern blot assays
Immediately after adenovirus infection, LNCaP cells were incubated with 100 pM of R1881. Cells without R1881 treatment served as the control. Total RNAs were prepared at 48 h after R1881 treatment. PSA/KLK3 and GAPDH cDNA probes were prepared and Northern hybridization was performed as described previously (Xu et al., 2000) .
Luciferase assays
LNCaP cells were plated into six-well plate in the appropriate medium with 10% cFBS for 5 days (5 Â 10 4 cells/well) before infection. At 24 h after adenovirus infection, the transfection was performed using Lipofectamine (Invitrogen, Carlsbad, CA, USA). The AR inducible reporter plasmid PSA-LUC (3 mg/well) (Segawa et al., 1998) , and an internal control plasmid pRL-TK (0.3 mg/well, Promega, Madison, WI, USA) were co-transfected into cells. The cells were cultured for 48 h in the presence or absence of R1881 (5 nM). Luciferase activity was measured by luminometer using the Dual-luciferase reporter assay system (Promega, Madison, WI, USA).
Colony formation assays
LNCaP cells were plated into 60 mm dishes in the appropriate medium with 10% cFBS for 5 days (5 Â 10 4 cells/well). Coinfection was performed with Ad-wtp53 and Ad-wtAR, Ad-mtAR (T877A) or Ad-control in the absence or presence of R1881 (10 pM). To assess the effect of mt AR (T877A) expression on cell growth inhibition mediated by endogenous p53, LNCaP cells were infected with Ad-wtAR, Ad-mtAR (T877A) or Ad-control. At 24 h after adenovirus infection, LNCaP cells were treated with Dx (0.2 mg/ml) in the absence or presence of R1881 (10 pM). The medium was changed every three days. On day 14, cells were fixed with PBS-2% formaldehyde and stained with crystal violet. Colonies visible in each dish were counted by Open-Lab software (Leica, Bannockburn, IL, USA) and displayed as histograms (M7s.d., n ¼ 3). For each group, a photograph of a representative dish is shown. The experiment was performed in triplicate.
Apoptotic DNA ladder analysis LNCaP cells were plated into 60 mm dishes in the appropriate medium with 10% cFBS for five days (5 Â 10 4 cells/dish). Infection was performed with Ad-wtAR, Ad-mtAR (T877A) or Ad-control. At 24 h after adenovirus infection, LNCaP cells were cultured in appropriate medium with Dx (0.2 mg/ml) in the absence or presence of R1881 (10 pM) for 5 days and cells were harvested for apoptosis associated DNA ladder analysis using Apoptotic DNA Ladder kit (Roche, Indianapolis, IN, USA).
Abbreviations AR, androgen receptor; wt, wild-type; mt, mutant; CaP, prostate cancer; FBS, fetal bovine serum; cFBS, charcoal/ dextran stripped FBS; pfu, plaque-forming unit; GAPDH, glyceraldehyde phosphate dehydrogenase; PSA, prostate specific antigen; Dx, doxorubicin.
